person · Reporting owner

Aurentz Vincent

Disclosed activity across 3 companies

Tapewire entity: 34472
SEC CIK: 0001657494

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Inhibikase Therapeutics, Inc.IKT · Entity 5838	Director	June 26, 2026	June 30, 2026
Longboard Pharmaceuticals, Inc.LBPH · Entity 85536	Director	December 02, 2024	December 03, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Inhibikase Therapeutics, Inc.

Report date June 26, 2026 · Filed June 30, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.91 · Expires 2036-06-26	Direct	155,000	Reported balance After 2026-06-26 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-26 · Grant · Acquired 155,000 · Balance 155,000 F1: The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.

Filing footnotes · ownership attribution and instrument terms

F1: The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.

Longboard Pharmaceuticals, Inc.

Report date December 02, 2024 · Filed December 03, 2024

Security / award	Ownership account	Disclosure context
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.10 · Expires 2031-09-13	Direct	Reported balance After 2024-12-02 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-12-02 · Disposition to issuer · Disposed 12,367 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F2: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.10 · Expires 2031-09-13	Direct	Reported balance After 2024-12-02 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-12-02 · Disposition to issuer · Disposed 7,214 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F2: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.40 · Expires 2032-05-23	Direct	Reported balance After 2024-12-02 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-12-02 · Disposition to issuer · Disposed 12,367 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F2: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.06 · Expires 2033-05-24	Direct	Reported balance After 2024-12-02 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-12-02 · Disposition to issuer · Disposed 12,500 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F2: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.94 · Expires 2034-05-22	Direct	Reported balance After 2024-12-02 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-12-02 · Disposition to issuer · Disposed 22,500 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F2: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger").

F2: On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ARENA PHARMACEUTICALS INC

Report date March 11, 2022 · Filed March 11, 2022

Section 16 reporting ended · disclosed 2022-03-11. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2022-03-11 transaction · row 3 3 source rows · reconciled sequence Row 1 · 2022-03-11 · Other · Disposed 27,842 · Balance 28,122 F1: Reflects disposition of Issuer common stock with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated December 12, 2021, by and among the Issuer, Pfizer Inc. ("Parent") and Antioch Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger (the "Merger") between Issuer and Merger Sub on March 11, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock, $0.0001 par value per share ("Issuer Common Stock"), was cancelled, retired and converted into the right to receive an amount equal to $100.00 in cash, without interest thereon (the "Merger Consideration"), subject to any required withholding of taxes. F2: Includes 842 shares acquired on March 2, 2022, pursuant to Arena's 2019 Employee Stock Purchase Plan. Row 2 · 2022-03-11 · Other · Disposed 6,660 · Balance 21,462 F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Issuer under an Issuer Stock Plan, except any restricted stock unit that was granted after December 12, 2021, (each, an "Issuer RSU"), that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration, subject to any required withholding of taxes. Row 3 · 2022-03-11 · Other · Disposed 21,462 · Balance 0 F4: Pursuant to the Merger Agreement, as of the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Company after December 12, 2021 under the Issuer's 2021 Long-Term Incentive Plan (each, a "2022 Issuer RSU") that was unvested and outstanding as of immediately prior to the Effective Time was substituted automatically with a Parent restricted stock unit with respect to that number of shares of Parent common stock that is equal to the product obtained by multiplying (1) the total number of Issuer Common Stock subject to the 2022 Issuer RSU immediately prior to the Effective Time by (2) the RSU Exchange Ratio (as defined in the Merger Agreement).
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.10	Direct	Reported balance After 2022-03-11 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-03-11 · Disposition to issuer · Disposed 45,000 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.60	Direct	Reported balance After 2022-03-11 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2022-03-11 · Disposition to issuer · Disposed 77,000 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.60	Direct	Reported balance After 2022-03-11 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2022-03-11 · Disposition to issuer · Disposed 94,976 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.94	Direct	Reported balance After 2022-03-11 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2022-03-11 · Disposition to issuer · Disposed 75,000 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.60	Direct	Reported balance After 2022-03-11 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2022-03-11 · Disposition to issuer · Disposed 70,000 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $80.08	Direct	Reported balance After 2022-03-11 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2022-03-11 · Disposition to issuer · Disposed 38,850 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes.
Employee Performance Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-03-11 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2022-03-11 · Disposition to issuer · Disposed 15,200 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit granted by the Issuer under an Issuer Stock Plan that was subject to performance-based vesting conditions (each, an "Issuer PRSU") that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration (with all the performance-based vesting conditions associated with such Issuer PRSU being deemed achieved at the greater of actual completed performance at the Effective Time or at target for any Issuer PRSU), subject to any required withholding of taxes.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects disposition of Issuer common stock with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated December 12, 2021, by and among the Issuer, Pfizer Inc. ("Parent") and Antioch Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger (the "Merger") between Issuer and Merger Sub on March 11, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock, $0.0001 par value per share ("Issuer Common Stock"), was cancelled, retired and converted into the right to receive an amount equal to $100.00 in cash, without interest thereon (the "Merger Consideration"), subject to any required withholding of taxes.

F2: Includes 842 shares acquired on March 2, 2022, pursuant to Arena's 2019 Employee Stock Purchase Plan.

F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Issuer under an Issuer Stock Plan, except any restricted stock unit that was granted after December 12, 2021, (each, an "Issuer RSU"), that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration, subject to any required withholding of taxes.

F4: Pursuant to the Merger Agreement, as of the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Company after December 12, 2021 under the Issuer's 2021 Long-Term Incentive Plan (each, a "2022 Issuer RSU") that was unvested and outstanding as of immediately prior to the Effective Time was substituted automatically with a Parent restricted stock unit with respect to that number of shares of Parent common stock that is equal to the product obtained by multiplying (1) the total number of Issuer Common Stock subject to the 2022 Issuer RSU immediately prior to the Effective Time by (2) the RSU Exchange Ratio (as defined in the Merger Agreement).

F5: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes.

F6: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit granted by the Issuer under an Issuer Stock Plan that was subject to performance-based vesting conditions (each, an "Issuer PRSU") that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration (with all the performance-based vesting conditions associated with such Issuer PRSU being deemed achieved at the greater of actual completed performance at the Effective Time or at target for any Issuer PRSU), subject to any required withholding of taxes.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 09, 2019 Filed Sep 10, 2019 21:05 UTC	ARENA PHARMACEUTICALS INC ARNA · Entity 94856	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	10,000	$0.00 Strike: $14.60	$0.00	Disclosure SEC source: 0001209191-19-049105 · doc4.xml · derivative · entry 7 Aurentz Vincent · CIK 0001657494 · Executive VP and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,500 Underlying: Common Stock · 10,000 shares Expires 2024-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The options vest over four years and are exercisable once vested. 25% vested and became exercisable on February 13, 2018. The remainder of the options vest in thirty-six equal monthly installments (except as otherwise necessary to avoid vesting of a fractional share), with the first installment vesting on March 13, 2018, and the thirty-sixth installment vesting on February 13, 2021. Read SEC document
September 09, 2019 Filed Sep 10, 2019 21:05 UTC	ARENA PHARMACEUTICALS INC ARNA · Entity 94856	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	25,000	$0.00 Strike: $17.10	$0.00	Disclosure SEC source: 0001209191-19-049105 · doc4.xml · derivative · entry 6 Aurentz Vincent · CIK 0001657494 · Executive VP and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 25,000 shares Expires 2023-08-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The options vest over four years and are exercisable once vested. 25% vested and became exercisable on August 15, 2017. The remainder of the options vest in thirty-six equal monthly installments (except as otherwise necessary to avoid vesting of a fractional share), with the first installment vesting on September 15, 2017, and the thirty-sixth installment vesting on August 15, 2020. Read SEC document
September 09, 2019 Filed Sep 10, 2019 21:05 UTC	ARENA PHARMACEUTICALS INC ARNA · Entity 94856	SaleCommon Stock	20,328	$51.23	$1,041,501.01	Disclosure SEC source: 0001209191-19-049105 · doc4.xml · nonDerivative · entry 5 Aurentz Vincent · CIK 0001657494 · Executive VP and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.54, inclusive. Read SEC document
September 09, 2019 Filed Sep 10, 2019 21:05 UTC	ARENA PHARMACEUTICALS INC ARNA · Entity 94856	SaleCommon Stock	44,672	$50.48	$2,255,198.91	Disclosure SEC source: 0001209191-19-049105 · doc4.xml · nonDerivative · entry 4 Aurentz Vincent · CIK 0001657494 · Executive VP and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,328 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.05 to $50.99, inclusive. The reporting person undertakes to provide Arena Pharmaceuticals, Inc., any security holder of Arena Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnotes 2 and 3 to this Form 4. Read SEC document
September 09, 2019 Filed Sep 10, 2019 21:05 UTC	ARENA PHARMACEUTICALS INC ARNA · Entity 94856	Exercise / conversionCommon Stock	30,000	$35.60	$1,068,000.00	Disclosure SEC source: 0001209191-19-049105 · doc4.xml · nonDerivative · entry 3 Aurentz Vincent · CIK 0001657494 · Executive VP and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 09, 2019 Filed Sep 10, 2019 21:05 UTC	ARENA PHARMACEUTICALS INC ARNA · Entity 94856	Exercise / conversionCommon Stock	10,000	$14.60	$146,000.00	Disclosure SEC source: 0001209191-19-049105 · doc4.xml · nonDerivative · entry 2 Aurentz Vincent · CIK 0001657494 · Executive VP and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 09, 2019 Filed Sep 10, 2019 21:05 UTC	ARENA PHARMACEUTICALS INC ARNA · Entity 94856	Exercise / conversionCommon Stock	25,000	$17.10	$427,500.00	Disclosure SEC source: 0001209191-19-049105 · doc4.xml · nonDerivative · entry 1 Aurentz Vincent · CIK 0001657494 · Executive VP and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 04, 2019 Filed Jan 8, 2019 21:01 UTC	ARENA PHARMACEUTICALS INC ARNA · Entity 94856	GrantEmployee Performance Restricted Stock Unit · Derivative	18,000	$0.00	$0.00	Disclosure SEC source: 0001209191-19-002951 · doc4.xml · derivative · entry 2 Aurentz Vincent · CIK 0001657494 · Executive VP and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2022-01-03 F2 · derivative.exercise_price: Each Employee Performance Restricted Stock Unit ("PRSU") represents a contingent right to receive shares of Arena's common stock, which shares shall vest, if at all, upon the closing price of Arena's common stock (the "Closing Price") reaching certain thresholds during the three-year performance period from January 4, 2019 through January 3, 2022 (the "Performance Period") and satisfaction of a continuing service requirement. F3 · shares: The number of shares that may vest is based on the Closing Price during the Performance Period. If, on 5 consecutive or 10 non-consecutive trading days during the Performance Period, the Closing Price equals or exceeds $60, $67.50 or $75, and the reporting person thereafter satisfies a continuing service requirement, the PRSUs are deemed vested at 50%, 100% or 200%, respectively, of the target amount reported in Column 7 (subject, in the event of a change of control, to additional vesting in circumstances where the per share transaction consideration falls in between the dollar values listed above), and the reporting person will receive at or following the time of vesting a number of shares equal to the achieved percentage multiplied by the total number of PRSUs. For the avoidance of doubt, shares may be issued following achievement of each price threshold, and the maximum number of shares that may be issued pursuant to the PRSUs equals 200% of the number of PRSUs reported in Column 5. F3 · derivative.exercise_date: The number of shares that may vest is based on the Closing Price during the Performance Period. If, on 5 consecutive or 10 non-consecutive trading days during the Performance Period, the Closing Price equals or exceeds $60, $67.50 or $75, and the reporting person thereafter satisfies a continuing service requirement, the PRSUs are deemed vested at 50%, 100% or 200%, respectively, of the target amount reported in Column 7 (subject, in the event of a change of control, to additional vesting in circumstances where the per share transaction consideration falls in between the dollar values listed above), and the reporting person will receive at or following the time of vesting a number of shares equal to the achieved percentage multiplied by the total number of PRSUs. For the avoidance of doubt, shares may be issued following achievement of each price threshold, and the maximum number of shares that may be issued pursuant to the PRSUs equals 200% of the number of PRSUs reported in Column 5. F3 · derivative.underlying_shares: The number of shares that may vest is based on the Closing Price during the Performance Period. If, on 5 consecutive or 10 non-consecutive trading days during the Performance Period, the Closing Price equals or exceeds $60, $67.50 or $75, and the reporting person thereafter satisfies a continuing service requirement, the PRSUs are deemed vested at 50%, 100% or 200%, respectively, of the target amount reported in Column 7 (subject, in the event of a change of control, to additional vesting in circumstances where the per share transaction consideration falls in between the dollar values listed above), and the reporting person will receive at or following the time of vesting a number of shares equal to the achieved percentage multiplied by the total number of PRSUs. For the avoidance of doubt, shares may be issued following achievement of each price threshold, and the maximum number of shares that may be issued pursuant to the PRSUs equals 200% of the number of PRSUs reported in Column 5. F3 · balance_after: The number of shares that may vest is based on the Closing Price during the Performance Period. If, on 5 consecutive or 10 non-consecutive trading days during the Performance Period, the Closing Price equals or exceeds $60, $67.50 or $75, and the reporting person thereafter satisfies a continuing service requirement, the PRSUs are deemed vested at 50%, 100% or 200%, respectively, of the target amount reported in Column 7 (subject, in the event of a change of control, to additional vesting in circumstances where the per share transaction consideration falls in between the dollar values listed above), and the reporting person will receive at or following the time of vesting a number of shares equal to the achieved percentage multiplied by the total number of PRSUs. For the avoidance of doubt, shares may be issued following achievement of each price threshold, and the maximum number of shares that may be issued pursuant to the PRSUs equals 200% of the number of PRSUs reported in Column 5. Read SEC document
January 04, 2019 Filed Jan 8, 2019 21:01 UTC	ARENA PHARMACEUTICALS INC ARNA · Entity 94856	GrantEmployee Stock Option (right to buy) · Derivative	75,000	$0.00 Strike: $40.94	$0.00	Disclosure SEC source: 0001209191-19-002951 · doc4.xml · derivative · entry 1 Aurentz Vincent · CIK 0001657494 · Executive VP and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2026-01-04 F1 · derivative.exercise_date: The options vest over four years, with 25% of the shares subject to the option vesting on January 4, 2020, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested. Read SEC document
January 19, 2018 Filed Jan 22, 2018 17:31 UTC	ARENA PHARMACEUTICALS INC ARNA · Entity 94856	GrantEmployee Stock Option (right to buy) · Derivative	130,000	$0.00 Strike: $35.60	$0.00	Disclosure SEC source: 0001209191-18-004776 · doc4.xml · derivative · entry 1 Aurentz Vincent · CIK 0001657494 · Executive VP and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2025-01-19 F1 · derivative.exercise_date: The options vest over four years, with 25% of the shares subject to the option vesting on January 19, 2019, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested. Read SEC document
February 13, 2017 Filed Feb 14, 2017 20:19 UTC	ARENA PHARMACEUTICALS INC ARNA · Entity 94856	GrantEmployee Stock Option (right to buy) · Derivative	995,000	$0.00 Strike: $1.46	$0.00	Disclosure SEC source: 0001209191-17-010897 · doc4.xml · derivative · entry 1 Aurentz Vincent · CIK 0001657494 · Executive VP and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 995,000 Underlying: Common Stock · 995,000 shares Expires 2024-02-13 F1 · derivative.exercise_date: The options vest over four years, with 25% of the shares subject to the option vesting on February 13, 2018, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.